As our company has grown in both market and product lines, it has become rapidly clear that our company needs to expand the production facilities. Currently, we have two production lines, one for dry tablets and one for injectable sterile pharmaceuticals. This limited production facility has hampered our market expansion efforts to meet demands for our products and to comply with GMP recommendations.

We recently acquired a suspension line that makes us able to provide water insoluble powders suspensions in water. This line contains a nanomil that breaks powder into nonparticles and makes possible a high quality products.

Another step is our products registration over the CIS countries, that means time and resource costly. We will currently start exporting only to Ukraine, country that accepted some of our drugs and proceeded with registration, but we are doing all efforts to register all medicines we produce.

We are in the process of obtaining certification of our products in the Ukraine region and hope to make our products available there soon. Afterwards, we will seek approval in Russia and the other CIS nations.